Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis

BACKGROUND: In recent years, immune checkpoint inhibitors (ICIs) including atezolizumab, durvalumab, pembrolizumab, and nivolumab have reported their efficacy and safety profile in patients with extensive-stage small cell lung cancer (ES-SCLC). However, given the diverse efficacy and inconsistent sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jianxin, Wang, Junhui, Xu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
3600
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051984/
https://www.ncbi.nlm.nih.gov/pubmed/33847617
http://dx.doi.org/10.1097/MD.0000000000025180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051984/
https://www.ncbi.nlm.nih.gov/pubmed/33847617
http://dx.doi.org/10.1097/MD.0000000000025180

Ejemplares similares